Thompson Siegel & Walmsley’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Thompson Siegel & Walmsley’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,500	Closed	-$350K	–	703
2020 Q3	$350K	Buy	+4,500	New	+$310K	0.01%	287
2019 Q4	–	Sell	-5,000	Closed	-$136K	–	915
2019 Q3	$136K	Sell	5,000 -9,000	-64%	-$233K	﹤0.01%	412
2019 Q2	$337K	Sell	14,000 -14,000	-50%	-$355K	﹤0.01%	354
2019 Q1	$740K	Buy	+28,000	New	+$663K	0.01%	297

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Thompson Siegel & Walmsley's HZNP Position: Q4 2020 in Review

Thompson Siegel & Walmsley sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 4,500 shares — an estimated $350K sold.

Thompson Siegel & Walmsley first reported a position in HZNP in Q1 2019 and held it in 4 quarters. The position peaked at $740K in Q1 2019. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

Thompson Siegel & Walmsley reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
Thompson Siegel & Walmsley sold 4,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $350K.
Thompson Siegel & Walmsley first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 4 quarters.
Thompson Siegel & Walmsley's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $740K in Q1 2019.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2020, filed 8 Feb 2021.